Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT04004221 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04004221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04004221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2017
Completion date
March 11, 2021
Enrollment
113 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic urothelial bladder cancer